SKYSCRAPER-03: a phase III study of tiragolumab plus atezolizumab versus durvalumab in locally advanced, unresectable, stage III NSCLC after platinum-based concurrent chemoradiation

Annals of Oncology 2026

View at publisher
Authors: Heather A. Wakelee, M-J. Ahn, Jeffrey D. Bradley, Sanjay Popat, Karen L. Kelly, A-M. Baird, Özgür Özyılkan, J. Yu, S.Y. Lee, N. Yanagitani, Melissa Lynne Johnson, Alfredo Sánchez-Hernández
+10 more A. Szczesna, Kristof Cuppens, E. Yao, C. Parsons, C. Matheny, Zilu Zhang, Maya N. White, J. Hsu, Namrata S. Patil, Rafał Dziadziuszko
DOI: 10.1016/j.annonc.2026.07.414
Cited by: 1
References: 31

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers HER2/EGFR in Cancer Research Prostate Cancer Treatment and Research

Publication details

Journal / source
Annals of Oncology
Publisher
Elsevier BV
Publication date
1 August 2026
Language
EN